Lisbon, July 14, 2026 (Lusa) - Portuguese drug manufacturer Hovione has completed an investment of over €40 million with the opening of a new production line at its pill development and manufacturing centre in Loures, strengthening its capacity to export complex medicines.

The investment in the production facility, inaugurated on Tuesday in the presence of the minister for the economy, Manuel Castro Almeida, will add 50 new skilled jobs to Hovione’s plant in Loures, the group’s main industrial, scientific and technological hub, which already employs around 1,250 staff.

In a statement, Hovione said that the new production line, equipped with state-of-the-art technology, will enable production volumes to be adjusted “to the needs of each project”.

“The new batch production unit now represents the next stage in the development of this centre, expanding the company’s capacity to handle different types of medicines and production scales,” the press release added.

With this investment, which increases production space by 25%, the Loures plant is further established as “the main industrial, scientific and technological centre of Hovione’s global network, which counts 19 of the world’s 20 largest pharmaceutical companies among its clients”.

In 2022, Hovione invested in a new-generation production line dedicated to the continuous manufacture of pills in Loures.

The chemical and pharmaceutical group Hovione was founded over 60 years ago in Portugal by Ivan and Diane Villax. It has four manufacturing plants in the US, Portugal, Ireland and China, and development laboratories in Lisbon, Portugal and New Jersey (US), employing over 2,600 staff.

Most of Hovione’s production is exported, with the US as its main destination.

CT/ADB // ADB.

Lusa